Phil F Cheng

List of Publications by Citations

Source: https://exaly.com/author-pdf/8588895/phil-f-cheng-publications-by-citations.pdf

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77
papers2,071
citations24
h-index43
g-index92
ext. papers2,870
ext. citations8
avg, IF4.7
L-index

#	Paper	IF	Citations
77	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. <i>Nature Communications</i> , 2015 , 6, 6051	17.4	211
76	sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. <i>Nature</i> , 2016 , 532, 250-4	50.4	205
75	Systematic classification of melanoma cells by phenotype-specific gene expression mapping. <i>Pigment Cell and Melanoma Research</i> , 2012 , 25, 343-53	4.5	113
74	Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2018 , 78, 1308-1320	10.1	109
73	Hypoxia contributes to melanoma heterogeneity by triggering HIF1Edependent phenotype switching. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 2436-2443	4.3	97
72	Proteomic analysis of human mesenchymal stromal cell secretomes: a systematic comparison of the angiogenic potential. <i>Npj Regenerative Medicine</i> , 2019 , 4, 8	15.8	73
71	EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation. <i>Cancer Cell</i> , 2018 , 34, 69-84.e14	24.3	71
70	Small molecule promotes Eatenin citrullination and inhibits Wnt signaling in cancer. <i>Nature Chemical Biology</i> , 2018 , 14, 94-101	11.7	66
69	Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 1289-97	12.9	64
68	Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma. <i>Cancer Immunology Research</i> , 2019 , 7, 77-85	12.5	61
67	Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma. <i>PLoS Genetics</i> , 2015 , 11, e1004877	6	59
66	Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. <i>Genome Biology</i> , 2015 , 16, 42	18.3	48
65	Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL. <i>Clinical Cancer Research</i> , 2016 , 22, 2020-31	12.9	44
64	low neurotrophin receptor CD271 regulates phenotype switching in melanoma. <i>Nature Communications</i> , 2017 , 8, 1988	17.4	43
63	E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. <i>Cancer Discovery</i> , 2018 , 8, 568-581	24.4	41
62	CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 2010-2023	4.3	41
61	Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. <i>Molecular Cancer</i> , 2018 , 17, 59	42.1	41

(2016-2016)

60	Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. <i>Oncotarget</i> , 2016 , 7, 77163-77174	3.3	39	
59	Melanoma Immunotherapy: Next-Generation Biomarkers. <i>Frontiers in Oncology</i> , 2018 , 8, 178	5.3	38	
58	Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. <i>Cell Reports</i> , 2018 , 25, 3564-3572.e4	10.6	30	
57	Osmoregulatory function of large vacuoles found in notochordal cells of the intervertebral disc running title: an osmoregulatory vacuole. <i>MCB Molecular and Cellular Biomechanics</i> , 2007 , 4, 227-37	1.2	29	
56	SMAD signaling promotes melanoma metastasis independently of phenotype switching. <i>Journal of Clinical Investigation</i> , 2019 , 129, 2702-2716	15.9	28	
55	Data mining The Cancer Genome Atlas in the era of precision cancer medicine. <i>Swiss Medical Weekly</i> , 2015 , 145, w14183	3.1	27	
54	Ingenol Mebutate Signals via PKC/MEK/ERK in Keratinocytes and Induces Interleukin Decoy Receptors IL1R2 and IL13RA2. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2132-42	6.1	25	
53	Basal cell carcinomas in a tertiary referral centre: a systematic analysis. <i>British Journal of Dermatology</i> , 2014 , 171, 1066-72	4	24	
52	Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho. <i>Clinical Cancer Research</i> , 2017 , 23, 3181-3190	12.9	23	
51	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. <i>PLoS ONE</i> , 2015 , 10, e0139438	3.7	23	
50	Loss of Ezh2 promotes a midbrain-to-forebrain identity switch by direct gene derepression and Wnt-dependent regulation. <i>BMC Biology</i> , 2015 , 13, 103	7.3	21	
49	The ALPK1/TIFA/NF- B axis links a bacterial carcinogen to R-loop-induced replication stress. <i>Nature Communications</i> , 2020 , 11, 5117	17.4	21	
48	Sox2 is dispensable for primary melanoma and metastasis formation. <i>Oncogene</i> , 2017 , 36, 4516-4524	9.2	20	
47	The EMT Transcription Factor ZEB2 Promotes Proliferation of Primary and Metastatic Melanoma While Suppressing an Invasive, Mesenchymal-Like Phenotype. <i>Cancer Research</i> , 2020 , 80, 2983-2995	10.1	19	
46	A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma. <i>Neoplasia</i> , 2018 , 20, 218-225	6.4	18	
45	MITF reprograms the extracellular matrix and focal adhesion in melanoma. <i>ELife</i> , 2021 , 10,	8.9	16	
44	Metastatic melanoma moves on: translational science in the era of personalized medicine. <i>Cancer and Metastasis Reviews</i> , 2017 , 36, 7-21	9.6	15	
43	PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas. <i>Oncotarget</i> , 2016 , 7, 75551-75560	3.3	15	

42	Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland. <i>Melanoma Research</i> , 2017 , 27, 358-368	3.3	14
41	Transcriptional repression of IFNII by ATF2 confers melanoma resistance to therapy. <i>Oncogene</i> , 2015 , 34, 5739-48	9.2	14
40	Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?. <i>Melanoma Research</i> , 2017 , 27, 231-237	3.3	11
39	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 2242-2252.e7	4.3	11
38	Metastatic melanoma cell lines do not secrete IL-1[but promote IL-1[broduction from macrophages. <i>Journal of Dermatological Science</i> , 2014 , 74, 167-9	4.3	11
37	A genome-wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS-mutant melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020 , 33, 334-344	4.5	11
36	Proteomic identification of a marker signature for MAPKi resistance in melanoma. <i>EMBO Journal</i> , 2019 , 38, e95874	13	11
35	The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 686-692	4.6	11
34	Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 667-675	4.6	11
33	The role of cyclin D1 and Ki-67 in the development and prognostication of thin melanoma. <i>Histopathology</i> , 2020 , 77, 460-470	7.3	9
32	The possible influence of osmotic poration on cell membrane water permeability. <i>Cryobiology</i> , 2009 , 58, 62-68	2.7	9
31	Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. <i>Clinical Proteomics</i> , 2018 , 15, 13	5	8
30	Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. <i>Melanoma Research</i> , 2018 , 28, 442-450	3.3	8
29	Prolonged Unfrozen Storage and Repeated Freeze-Thawing of SARS-CoV-2 Patient Samples Have Minor Effects on SARS-CoV-2 Detectability by RT-PCR. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 691-6	9 7 ·1	8
28	Medical bioinformatics in melanoma. Current Opinion in Oncology, 2018, 30, 113-117	4.2	8
27	profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. Oncolmmunology, 2015 , 4, e988458	7.2	7
26	Targeting complex, adaptive responses in melanoma therapy. Cancer Treatment Reviews, 2020, 86, 1019	9 97 .4	7
25	Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma. <i>Journal of Investigative Dermatology</i> , 2020 , 140, 878-890.e5	4.3	7

(2022-2020)

24	Activation of CD8 T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. <i>Cancer Immunology Research</i> , 2020 , 8, 1114-1121	12.5	7
23	Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma. <i>Current Opinion in Oncology</i> , 2016 , 28, 172-9	4.2	6
22	A Comparative Study of Real-Time RT-PCR-Based SARS-CoV-2 Detection Methods and Its Application to Human-Derived and Surface Swabbed Material. <i>Journal of Molecular Diagnostics</i> , 2021 , 23, 796-804	5.1	6
21	Methadone-Not a magic bullet in melanoma therapy. Experimental Dermatology, 2018, 27, 694-696	4	5
20	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. <i>Nature Communications</i> , 2021 , 12, 1434	17.4	5
19	Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis. <i>Cancers</i> , 2021 , 13,	6.6	5
18	An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel. <i>British Journal of Dermatology</i> , 2016 , 175, 966-978	4	4
17	Coexpression of SOX10/CD271 (p75(NTR)) and EGalactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients. <i>Dermatopathology (Basel, Switzerland)</i> , 2014 , 1, 35-46	1.9	3
16	Specific Activation of the CD271 Intracellular Domain in Combination with Chemotherapy or Targeted Therapy Inhibits Melanoma Progression. <i>Cancer Research</i> , 2021 , 81, 6044-6057	10.1	3
15	Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response. <i>European Journal of Cancer</i> , 2021 , 149, 37-48	7.5	3
14	NRAS melanoma tumor formation is reduced by p38-MAPK14 activation in zebrafish models and NRAS-mutated human melanoma cells. <i>Pigment Cell and Melanoma Research</i> , 2021 , 34, 150-162	4.5	3
13	Lipoconstruct surface topography grating size influences vascularization onset in the dorsal skinfold chamber model. <i>Acta Biomaterialia</i> , 2020 , 106, 136-144	10.8	2
12	Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis. <i>Melanoma Research</i> , 2020 , 30, 552-561	3.3	2
11	Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases. <i>European Journal of Cancer</i> , 2021 , 156, 149-163	7.5	2
10	Melanoma patients with additional primary cancers: a single-center retrospective analysis. <i>Oncotarget</i> , 2019 , 10, 3373-3384	3.3	1
9	Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4. <i>Nature Communications</i> , 2021 , 12, 5056	17.4	1
8	Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer <i>Frontiers in Immunology</i> , 2021 , 12, 793992	8.4	О
7	Mycobacterial infection aggravates Helicobacter pylori-induced gastric preneoplastic pathology by redirection of de novo induced Treg cells <i>Cell Reports</i> , 2022 , 38, 110359	10.6	0

6	Survival and therapeutic response in patients with melanoma of unknown and known primary: a single-centre retrospective analysis. <i>European Journal of Dermatology</i> , 2020 , 30, 699-709	0.8	О
5	IL-6 blockade for prophylaxis and management of immune-related adverse events (irAEs) with anti-PD-1 based immunotherapy <i>Journal of Clinical Oncology</i> , 2021 , 39, 9553-9553	2.2	O
4	Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. <i>Journal of Dermatology</i> , 2015 , 42, 927-8	1.6	
3	Diffuse Cutaneous Melanosis Associated with Malignant Melanoma. <i>Annals of Dermatology</i> , 2015 , 27, 780-1	0.4	
2	568 Tumor-derived GDF-15 prevents therapy success of checkpoint inhibitors by blocking		
4	T-lymphocyte recruitment 2021 , 9, A597-A597		